| http://www.w3.org/ns/prov#value | - Bevacizumab, however, remained on the market, since it has been approved for the treatment of other cancer types [127].It is important to point out that the tumor response against an antiangiogenic agent may differ between tumor types and subtypes, and, as a result, the complex mechanisms involved in antiangiogenic therapy are still being uncovered.
|
